Page 293 - Haematologica Vol. 109 - July 2024

LETTER TO THE EDITOR
Received: September 8, 2023. Accepted: February 23, 2024. Early view: February 29, 2024.
©2024 Ferrata Storti Foundation Published under a CC BY-NC license
Disclosures
CLR reports receiving consulting fees and research funding from Helocyte Inc. DJD reports receiving fees for royalties, research funding, and fees for serving on the advisory board of Helocyte Inc. DJD is co-inventor on a patent application covering the design and construction of the synthetic modified vaccinia Ankara platform (PCT/US2021/016247); is co-inventor on a patent application covering the development of a COVID-19 vaccine (PCT/ US2021/032821); is an employee of City of Hope National Medical Center (Duarte, CA, USA), which developed and funded the vaccine trial; receives consulting fees, patent royalties, research funding, and fees for serving on the advisory board of Helocyte Inc.; in addition, DJD has two patents 8,580,276 and 9,675,689 that are licensed to Helocyte; is a co-inventor of the Patent Cooperation Treaty (PCT) application that covers the development of a COVID-19 vaccine (PCT/US2021/032821) licensed to GeoVax Labs Inc.; receives consulting fees and research support from GeoVax Labs Inc. DJD and CLR are co-inventors on a patent covering the “Vaccination of hematopoietic stem cell donors with cytomegalovirus Triplex composition” (PCT/US2023/032052).
Contributions
AP, WS, NK, and JC treated and clinically assessed the patients for
References
1. Khandelwal P, Millard HR, Thiel E, et al. Hematopoietic stem cell transplantation activity in pediatric cancer between 2008 and 2014 in the United States: a Center for International Blood and Marrow Transplant research report. Biol Blood Marrow Transplant. 2017;23(8):1342-1349.
2. Czyzewski K, Styczynski J, Giebel S, et al. Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation: lesson from the nationwide study. Ann Hematol. 2019;98(9):2197-2211.
3. Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119-127.
4. Zavras P, Su Y, Fang J, et al. Impact of preemptive therapy for cytomegalovirus on toxicities after allogeneic hematopoietic cell transplantation in clinical practice: a retrospective single- center cohort study. Biol Blood Marrow Transplant. 2020;26(8):1482-1491.
5. Abate D, Cesaro S, Cofano S, et al. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients. Transplantation. 2012;93(5):536-542.
6. Laberko A, Bogoyavlenskaya A, Shelikhova L, et al. Risk factors for and the clinical impact of cytomegalovirus and Epstein-Barr
adverse events and acute graft-versus-host disease. DJD and WS designed the study. YP, QZ, and TK performed specimen processing, reagent preparation, and immunological assays. CLR and YP analyzed the immune monitoring data. DY performed the statistical analyses. CLR and DJD wrote the initial manuscript; and all authors approved the final version.
Acknowledgments
We thank the patients and their parents, nurses, technicians, research coordinators and clinicians, and the staff at the City of Hope (COH) without whose support this trial could not have been conducted. MVA was provided under a Material Transfer Agreement to COH from the National Institute of Allergy and Infectious Diseases (NIAID), Laboratory of Viral Diseases (Dr. Bernard Moss, Director). The following reagents were obtained through the National Institute of Health (NIH) AIDS Reagent Program, Division of AIDS, NIAID, NIH: HCMV pp65 Peptide Pool (referred as pp65 library in the manuscript). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Funding
The study was supported by grants from the National Cancer Institute (NCI) 5R01 CA077544; NCI P30 CA033572; P50 SPORE CA107399; 1R01 CA181045; NCI-SAIC-Frederick 28XS061; 1R01 CA266783 and Helocyte Inc. (to DJD).
Data-sharing statement
The clinical trial protocol and the anonymized data presented in this study can be made available upon reasonable request.
virus infections in pediatric recipients of TCR-alpha/beta- and CD19-depleted grafts. Biol Blood Marrow Transplant. 2017;23(3):483-490.
7. Russo D, Schmitt M, Pilorge S, et al. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double- blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2023;11(2):e127-e135.
8. N PD, Cirincione A, Siver M, et al. Letermovir for cytomegalovirus prevention in adolescent patients following hematopoietic cell transplantation. J Pediatric Infect Dis Soc. 2022;11(7):337-340.
9. Su Y, Stern A, Karantoni E, et al. Impact of letermovir primary cytomegalovirus prophylaxis on 1-year mortality after allogeneic hematopoietic cell transplantation: a retrospective cohort study. Clin Infect Dis. 2022;75(5):795-804.
10. Zamora D, Duke ER, Xie H, et al. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. Blood. 2021;138(1):34-43.
11. Shafat MS, Mehra V, Peggs KS, Roddie C. Cellular therapeutic approaches to cytomegalovirus infection following allogeneic stem cell transplantation. Front Immunol. 2020;11:1694.
12. Pfeiffer T, Tzannou I, Wu M, et al. Posoleucel, an allogeneic,
Haematologica | 109 July 2024
2307